| Literature DB >> 35240412 |
Renyang Gu1, Ashik Amlani2, Ulrike Haberland3, Dan Hodson4, Matthew Streetly5, Michela Antonelli6, Isabel Dregely6, Vicky Goh7.
Abstract
OBJECTIVES: Objective evaluation of the extent of skeletal marrow involvement in multiple myeloma remains a clinical gap for CT. We aimed to develop a quantitative segmentation pipeline for dual energy CT and to assess whether quantified whole skeleton calcium-subtracted attenuation values correlate with biopsy-derived bone marrow infiltration in multiple myeloma.Entities:
Keywords: Calcium-subtracted attenuation; Dual-energy CT; Image Segmentation; Myeloma; Whole-body
Mesh:
Substances:
Year: 2022 PMID: 35240412 PMCID: PMC9026281 DOI: 10.1016/j.ejrad.2022.110223
Source DB: PubMed Journal: Eur J Radiol ISSN: 0720-048X Impact factor: 4.531
Fig. 1Study flowchart.
Fig. 260-year old female with a new diagnosis of myeloma (top row). Representative dual-energy CT images show multifocal disease and relatively diffuse marrow infiltration, particularly within the axial skeleton. Reconstructed coronal 90kVp (A); 150 kVp (B); weighted-average 120 kVp images (C); and colour-coded whole body rendered image (green representing infiltration) (D). 88-year old male with a new diagnosis of myeloma (bottom row). Representative dual-energy CT images show multifocal disease but patchy heterogeneous marrow infiltration. Reconstructed coronal 90kVp (E); 150 kVp (F); weighted-average 120 kVp images (G); and colour-coded whole body rendered image (green representing infiltration) (H).
Fig. 3Schematic showing workflow for whole skeleton segmentation and quantification. A: Coronal weighted-average 120 kVp image (bone windows); B: Initial segmentation with filtering and thresholding at 120HU; C: Segmentation following 2 iterations of the Chan-Vese morphological operation; D: Segmentation following further iterations to complete delineation and filling in (erosion) of the appendicular skeleton; E: Final segmentation mask overlaid on calcium-subtracted attenuation parametric map to generate whole skeleton histogram HU values.
Patient and disease characteristics.
| Male | 9 (43) | |
| Female | 12 (57) | |
| Monoclonal gammopathy of unknown significance | 3 (14) | |
| New diagnosis myeloma | 5 (24) | |
| Relapsed myeloma | 13 (62) | |
| IgG kappa | 12 (57) | |
| IgG lambda | 2 (10) | |
| Lambda light chain | 4 (19) | |
| IgA | 1 (5) | |
| Missing data | 2 (10) | |
| Stage I | 6 (29) | |
| Stage II | 4 (19) | |
| Stage III | 4 (19) | |
| Missing data | 7 (33) | |
| Normal range (120–150 g/L) | 9 (43) | |
| Below normal range (<120 g/L) | 12 (57) | |
| Normal range (48–84 μmol/L) | 8 (38) | |
| Above normal range (>84 μmol/L) | 11 (52) | |
| Below normal range (<48 μmol/L) | 2 (10) | |
| Normal range (2.15–2.55 mmol/L) | 15 (71) | |
| Above normal range(>2.55 mmol/L) | 1 (5) | |
| Below normal range(<2.15 mmol/L) | 4 (19) | |
| 10% | 3 (14) | |
| 11–60% | 6 (29) | |
| Above 60% | 6 (29) | |
| Missing data* | 6 (29) | |
| Alive | 13 (62) | |
| Deceased | 8 (38) | |
Histogram values derived from whole skeleton segmentation for each patient.
| 01 | Relapsed myeloma | −63.9 | −72.0 | 47.8 | 1.2 | 4.6 |
| 02 | Relapsed myeloma | −59.2 | −64.0 | 45.4 | 1.6 | 26.8 |
| 03 | Relapsed myeloma | −63.6 | −77.0 | 100.0 | 13.9 | 315.2 |
| 04 | New myeloma | −39.1 | −35.0 | 47.5 | 1.1 | 17.8 |
| 05 | Relapsed myeloma | −54.3 | −58.0 | 45.3 | 0.5 | 0.3 |
| 06 | Relapsed myeloma | −47.4 | −50.0 | 54.6 | 0.6 | 1.4 |
| 07 | New myeloma | −82.5 | −91.0 | 49.4 | 1.0 | 3.4 |
| 08 | Relapsed myeloma | −53.9 | −55.0 | 46.6 | 1.1 | 7.7 |
| 09 | Relapsed myeloma | −53.3 | −55.0 | 36.4 | 0.9 | 8.4 |
| 10 | Relapsed myeloma | −64.6 | −69.0 | 45.4 | 1.3 | 5.3 |
| 11 | New myeloma | −26.1 | −28.0 | 96.7 | 7.0 | 87.2 |
| 12 | Relapsed myeloma | −25.5 | −25.0 | 71.2 | 2.7 | 25.1 |
| 13 | MGUS – light chain | −58.1 | −79.0 | 108.8 | 5.0 | 31.1 |
| 14 | Relapsed myeloma | −41.9 | −46.0 | 80.7 | 7.6 | 96.2 |
| 15 | MGUS - IgA | −72.2 | −79.0 | 51.8 | 1.6 | 10.6 |
| 16 | New myeloma | −62.3 | −83.0 | 143.3 | 9.3 | 121.6 |
| 17 | Relapsed myeloma | −75.8 | −83.0 | 58.0 | 2.8 | 26.4 |
| 18 | MGUS – IgG kappa | −79.7 | −82.0 | 44.4 | 0.2 | 0.4 |
| 19 | Relapsed myeloma | −59.9 | −63.0 | 49.4 | 3.5 | 69.2 |
| 20 | New Myeloma | −66.3 | −84.0 | 81.3 | 9.8 | 224.4 |
| 21 | New Myeloma | −77.5 | −83.0 | 49.2 | 2.4 | 28.2 |
Abbreviation: MGUS = monoclonal gammopathy of unknown significance; SD = standard deviation
Fig. 4Correlation plots showing positive association of whole skeleton calcium-subtracted attenuation values with bone marrow biopsy (A); and negative association of whole skeleton calcium-subtracted attenuation values with haemoglobin level (B). All patients had new or relapsed myeloma with biopsy infiltration ≥ 10%).